Cargando…

Risks and Benefits of Prophylactic Transfusion before Cholecystectomy in Sickle Cell Disease

Preoperative transfusion (PT) reduces acute postoperative vaso-occlusive events (VOE) in sickle cell disease (SCD), but exposes patients to alloimmunization, encouraging a recent trend towards transfusion sparing. The aim of this study was to investigate the benefit–risk ratio of PT before cholecyst...

Descripción completa

Detalles Bibliográficos
Autores principales: Rambaud, Elise, Ranque, Brigitte, Tsiakyroudi, Sofia, Joseph, Laure, Bouly, Nathalie, Douard, Richard, François, Anne, Pouchot, Jacques, Arlet, Jean-Benoît
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319142/
https://www.ncbi.nlm.nih.gov/pubmed/35887750
http://dx.doi.org/10.3390/jcm11143986
_version_ 1784755477401305088
author Rambaud, Elise
Ranque, Brigitte
Tsiakyroudi, Sofia
Joseph, Laure
Bouly, Nathalie
Douard, Richard
François, Anne
Pouchot, Jacques
Arlet, Jean-Benoît
author_facet Rambaud, Elise
Ranque, Brigitte
Tsiakyroudi, Sofia
Joseph, Laure
Bouly, Nathalie
Douard, Richard
François, Anne
Pouchot, Jacques
Arlet, Jean-Benoît
author_sort Rambaud, Elise
collection PubMed
description Preoperative transfusion (PT) reduces acute postoperative vaso-occlusive events (VOE) in sickle cell disease (SCD), but exposes patients to alloimmunization, encouraging a recent trend towards transfusion sparing. The aim of this study was to investigate the benefit–risk ratio of PT before cholecystectomy on the occurrence of postoperative VOE. Adult SCD patients who underwent cholecystectomy between 2008 and 2019 in our center were included. Patients’ characteristics, collected retrospectively, were compared according to PT. A total of 79 patients were included, 66% of whom received PT. Gallbladder histopathology found chronic cholecystitis (97%) and gallstones (66%). Transfused patients underwent more urgent surgeries and had experienced more painful vaso-occlusive crises (VOC) in the month before surgery (p = 0.05). Four (8.5%) post-transfusion alloimmunizations occurred, and two of them caused a delayed hemolytic transfusion reaction (DHTR) (4.3%). The occurrence of postoperative VOE was similar between the groups (19.2% vs. 29.6%, p = 0.45). Though not statistically significant, a history of hospitalized VOC within 6 months prior to surgery seemed to be associated to postoperative VOE among non-transfused patients (75% vs. 31.6%, p = 0.10). PT before cholecystectomy exposes to risks of alloimmunization and DHTR that could be avoided in some patients. Recent VOCs appear to be associated with a higher risk of postoperative VOE and prompt the preemptive transfusion of these patients.
format Online
Article
Text
id pubmed-9319142
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93191422022-07-27 Risks and Benefits of Prophylactic Transfusion before Cholecystectomy in Sickle Cell Disease Rambaud, Elise Ranque, Brigitte Tsiakyroudi, Sofia Joseph, Laure Bouly, Nathalie Douard, Richard François, Anne Pouchot, Jacques Arlet, Jean-Benoît J Clin Med Article Preoperative transfusion (PT) reduces acute postoperative vaso-occlusive events (VOE) in sickle cell disease (SCD), but exposes patients to alloimmunization, encouraging a recent trend towards transfusion sparing. The aim of this study was to investigate the benefit–risk ratio of PT before cholecystectomy on the occurrence of postoperative VOE. Adult SCD patients who underwent cholecystectomy between 2008 and 2019 in our center were included. Patients’ characteristics, collected retrospectively, were compared according to PT. A total of 79 patients were included, 66% of whom received PT. Gallbladder histopathology found chronic cholecystitis (97%) and gallstones (66%). Transfused patients underwent more urgent surgeries and had experienced more painful vaso-occlusive crises (VOC) in the month before surgery (p = 0.05). Four (8.5%) post-transfusion alloimmunizations occurred, and two of them caused a delayed hemolytic transfusion reaction (DHTR) (4.3%). The occurrence of postoperative VOE was similar between the groups (19.2% vs. 29.6%, p = 0.45). Though not statistically significant, a history of hospitalized VOC within 6 months prior to surgery seemed to be associated to postoperative VOE among non-transfused patients (75% vs. 31.6%, p = 0.10). PT before cholecystectomy exposes to risks of alloimmunization and DHTR that could be avoided in some patients. Recent VOCs appear to be associated with a higher risk of postoperative VOE and prompt the preemptive transfusion of these patients. MDPI 2022-07-09 /pmc/articles/PMC9319142/ /pubmed/35887750 http://dx.doi.org/10.3390/jcm11143986 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rambaud, Elise
Ranque, Brigitte
Tsiakyroudi, Sofia
Joseph, Laure
Bouly, Nathalie
Douard, Richard
François, Anne
Pouchot, Jacques
Arlet, Jean-Benoît
Risks and Benefits of Prophylactic Transfusion before Cholecystectomy in Sickle Cell Disease
title Risks and Benefits of Prophylactic Transfusion before Cholecystectomy in Sickle Cell Disease
title_full Risks and Benefits of Prophylactic Transfusion before Cholecystectomy in Sickle Cell Disease
title_fullStr Risks and Benefits of Prophylactic Transfusion before Cholecystectomy in Sickle Cell Disease
title_full_unstemmed Risks and Benefits of Prophylactic Transfusion before Cholecystectomy in Sickle Cell Disease
title_short Risks and Benefits of Prophylactic Transfusion before Cholecystectomy in Sickle Cell Disease
title_sort risks and benefits of prophylactic transfusion before cholecystectomy in sickle cell disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319142/
https://www.ncbi.nlm.nih.gov/pubmed/35887750
http://dx.doi.org/10.3390/jcm11143986
work_keys_str_mv AT rambaudelise risksandbenefitsofprophylactictransfusionbeforecholecystectomyinsicklecelldisease
AT ranquebrigitte risksandbenefitsofprophylactictransfusionbeforecholecystectomyinsicklecelldisease
AT tsiakyroudisofia risksandbenefitsofprophylactictransfusionbeforecholecystectomyinsicklecelldisease
AT josephlaure risksandbenefitsofprophylactictransfusionbeforecholecystectomyinsicklecelldisease
AT boulynathalie risksandbenefitsofprophylactictransfusionbeforecholecystectomyinsicklecelldisease
AT douardrichard risksandbenefitsofprophylactictransfusionbeforecholecystectomyinsicklecelldisease
AT francoisanne risksandbenefitsofprophylactictransfusionbeforecholecystectomyinsicklecelldisease
AT pouchotjacques risksandbenefitsofprophylactictransfusionbeforecholecystectomyinsicklecelldisease
AT arletjeanbenoit risksandbenefitsofprophylactictransfusionbeforecholecystectomyinsicklecelldisease